<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">JCNR</journal-id><journal-title-group><journal-title>Journal of Clinical and Nursing Research</journal-title></journal-title-group><issn>2208-3685</issn><eissn>2208-3693</eissn><publisher><publisher-name>Bio-Byword Scientific Publishing Pty. Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26689/jcnr.v9i4.10401</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>Effects of 0.01% Atropine Eye Drops on Horizontal Meridian Choroidal Thickness Profile in Low to Moderate Myopic Children</title><url>https://artdesignp.com/journal/JCNR/9/4/10.26689/jcnr.v9i4.10401</url><author>TangYun,ChenXufei,DengXiaofeng,ZhangJunna,LiuLiping,DuChixin</author><pub-date pub-type="publication-year"><year>2025</year></pub-date><volume>9</volume><issue>4</issue><history><date date-type="pub"><published-time>2025-04-29</published-time></date></history><abstract>Purpose: To examine the changes in choroidal thickness (ChT) after 6-month topical treatment of 0.01% atropine eye drops in myopic children. Methods: A total of 46 low to moderate myopic children aged 8 to 12 years were recruited and received topical 0.01% atropine once a day for 6 months. Spherical equivalent (SE), axial length (AL), and ChT were measured at baseline, 3 months, and 6 months. Results: During the first and second 3-month treatment, there is no significant decrease in progression of SE and AL. Within the range of 3 mm from the temporal side of the fovea to the nasal side, no significant changes in ChT have been observed at any measuring points in low and moderate myopic participants. Changes in ChT were not significantly associated with gender or AL progression. Conclusion: A 6-month topical treatment of 0.01% atropine could not cause significant changes in ChT in myopic children.</abstract><keywords/></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>Holden BA, Fricke TR, Wilson DA, et al., 2016, Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 Through 2050. Ophthalmology, 123(5): 1036–1042.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><p>Williams KM, Bertelsen G, Cumberland P, et al., 2015, Increasing Prevalence of Myopia in Europe and the Impact of Education. Ophthalmology, 122(7): 1489–1497.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><p>Wang J, Ying GS, Fu X, et al., 2020, Prevalence of Myopia and Vision Impairment in School Students in Eastern China. BMC Ophthalmology, 20(1): 2.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><p>Chen C, Yao J, 2021, Efficacy and Adverse Effects of Atropine for Myopia Control in Children: A Meta-Analysis of Randomised Controlled Trials. Journal of Ophthalmology, 2021: 4274572.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><p>Chia A, Chua WH, Cheung YB, et al., 2012, Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2). Ophthalmology, 119: 347–354.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><p>Yam JC, Zhang XJ, Zhang Y, et al, 2022, Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report. Ophthalmology, 129(3): 308–321.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><p>Fu A, Stapleton F, Wei L, et al., 2020, Effect of Low-Dose Atropine on Myopia Progression, Pupil Diameter and Accommodative Amplitude: Low-Dose Atropine and Myopia Progression. British Journal of Ophthalmology, 104(11): 1535–1541.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><p>McBrien NA, Moghaddam HO, Reeder AP, 1993, Atropine Reduces Experimental Myopia and Eye Enlargement via a Nonaccommodative Mechanism. Investigative Ophthalmology &amp; Visual Science, 34(1): 205–215.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><p>Thomson K, Kelly T, Karouta C, et al., 2021, Insights into the Mechanism by Which Atropine Inhibits Myopia: Evidence Against Cholinergic Hyperactivity and Modulation of Dopamine Release. British Journal of Pharmacology, 178(22): 4501–4517.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><p>Fischer AJ, McKinnon LA, Nathanson NM, et al., 1998, Identification and Localization of Muscarinic Acetylcholine Receptors in the Ocular Tissues of the Chick. Journal of Comparative Neurology, 392(3): 273–284.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><p>Hamzah F, Shinojima A, Mori R, et al., 2014, Choroidal Thickness Measurement by Enhanced Depth Imaging and Swept-Source Optical Coherence Tomography in Central Serous Chorioretinopathy. BMC Ophthalmology, 14: 145.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><p>Kim SW, Oh J, Kwon SS, et al., 2011, Comparison of Choroidal Thickness Among Patients with Healthy Eyes, Early Age-Related Maculopathy, Neovascular Age-Related Macular Degeneration, Central Serous Chorioretinopathy, and Polypoidal Choroidal Vasculopathy. Retina, 31(9): 1904–1911.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><p>Wang XQ, Zeng LZ, Chen M, et al., 2021, A Meta-Analysis of Alterations in the Retina and Choroid in High Myopia Assessed by Optical Coherence Tomography Angiography. Ophthalmic Research, 64(6): 928–937.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><p>Alzaben Z, Cardona G, Zapata MA, et al., 2018, Interocular Asymmetry in Choroidal Thickness and Retinal Sensitivity in High Myopia. Retina, 38(8): 1620–1628.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><p>Yam JC, Jiang Y, Lee J, et al., 2022, The Association of Choroidal Thickening by Atropine with Treatment Effects for Myopia: Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study. American Journal of Ophthalmology, 237: 130–138.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B16" content-type="article"><label>16</label><element-citation publication-type="journal"><p>Chiang ST, Turnbull PRK, Phillips JR, 2020, Additive Effect of Atropine Eye Drops and Short-Term Retinal Defocus on Choroidal Thickness in Children with Myopia. Scientific Reports, 10(1): 18310.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B17" content-type="article"><label>17</label><element-citation publication-type="journal"><p>Ye L, Shi Y, Yin Y, et al., 2020, Effects of Atropine Treatment on Choroidal Thickness in Myopic Children. Investigative Ophthalmology &amp; Visual Science, 61(14): 15.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B18" content-type="article"><label>18</label><element-citation publication-type="journal"><p>Burfield HJ, Patel NB, Ostrin LA, 2018, Ocular Biometric Diurnal Rhythms in Emmetropic and Myopic Adults. Investigative Ophthalmology &amp; Visual Science, 59(12): 5176–5187.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B19" content-type="article"><label>19</label><element-citation publication-type="journal"><p>Zhao M, Yang XF, Jiao X, et al, 2016, The Diurnal Variation Pattern of Choroidal Thickness in Macular Region of Young Healthy Female Individuals Using Spectral Domain Optical Coherence Tomography. International Journal of Ophthalmology, 9(4): 561–566.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B20" content-type="article"><label>20</label><element-citation publication-type="journal"><p>Usui S, Ikuno Y, Akiba M, et al., 2012, Circadian Changes in Subfoveal Choroidal Thickness and the Relationship with Circulatory Factors in Healthy Subjects. Investigative Ophthalmology &amp; Visual Science, 53(4): 2300–2307.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B21" content-type="article"><label>21</label><element-citation publication-type="journal"><p>Liu S, He X, Wang J, et al., 2022, Association Between Axial Length Elongation and Spherical Equivalent Progression in Chinese Children and Adolescents. Ophthalmic and Physiological Optics, 42(5): 1133–1140.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B22" content-type="article"><label>22</label><element-citation publication-type="journal"><p>Fu A, Stapleton F, Wei L, et al., 2021, Risk Factors for Rapid Axial Length Elongation with Low Concentration Atropine for Myopia Control. Scientific Reports, 11(1): 11729.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B23" content-type="article"><label>23</label><element-citation publication-type="journal"><p>Yam JC, Jiang Y, Tang SM, et al., 2019, Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology, 126(1): 113–124.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B24" content-type="article"><label>24</label><element-citation publication-type="journal"><p>Yam JC, Li FF, Zhang X, et al., 2020, Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. Ophthalmology, 127(7): 910–919.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B25" content-type="article"><label>25</label><element-citation publication-type="journal"><p>Li W, Jiang R, Zhu Y, et al., 2020, Effect of 0.01% Atropine Eye Drops on Choroidal Thickness in Myopic Children. Journal Français d’Ophtalmologie, 43(9): 862–868.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B26" content-type="article"><label>26</label><element-citation publication-type="journal"><p>Hao Q, Zhao Q, 2021, Changes in Subfoveal Choroidal Thickness in Myopic Children with 0.01% Atropine, Orthokeratology, or Their Combination. International Ophthalmology, 41(9): 2963–2971.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
